The University of California, Los Angeles School of Medicine—known as the David Geffen School of Medicine at UCLA —is an accredited medical school located in Los Angeles, California, United States. The school was renamed in 2001 in honor of media mogul David Geffen who donated $200 million in unrestricted funds.

During the past decade, David Geffen School of Medicine at UCLA conducted 99 clinical trials. In the 10-year time frame, 99 clinical trials started and 75 clinical trials were completed, i.e. on average, 75.8% percent of trials that started reached the finish line to date. In the past 5 years, 39 clinical trials started and 43 clinical trials were completed. i.e. 110.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "David Geffen School of Medicine at UCLA" #1 sponsor was "University of California, Los Angeles" with 14 trials, followed by "Pfizer" with 10 trials sponsored, "National Institute of Allergy and Infectious Diseases (NIAID)" with 8 trials sponsored, "Actelion" with 7 trials sponsored and "Hoffmann-La Roche" with 7 trials sponsored. Other sponsors include 191 different institutions and companies that sponsored additional 128 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "David Geffen School of Medicine at UCLA" #1 collaborator was "National Cancer Institute (NCI)" with 5 trials as a collaborator, "National Institute of Mental Health (NIMH)" with 4 trials as a collaborator, "National Institute on Drug Abuse (NIDA)" with 4 trials as a collaborator, "University of California, Los Angeles" with 4 trials as a collaborator and "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 3 trials as a collaborator. Other collaborators include 79 different institutions and companies that were collaborators in the rest 80 trials.

According to Clinical.Site data, the most researched conditions in "David Geffen School of Medicine at UCLA" are "HIV Infections" (19 trials), "Idiopathic Pulmonary Fibrosis" (11 trials), "Pulmonary Arterial Hypertension" (9 trials), "Duchenne Muscular Dystrophy" (7 trials) and "Multiple Myeloma" (6 trials). Many other conditions were trialed in "David Geffen School of Medicine at UCLA" in a lesser frequency.

Most popular intervention types in "David Geffen School of Medicine at UCLA" are "Drug" (191 trials), "Biological" (23 trials), "Other" (15 trials), "Behavioral" (7 trials) and "Procedure" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (47 trials), "placebo" (8 trials), "Cyclophosphamide" (6 trials), "Dexamethasone" (4 trials) and "Soticlestat" (4 trials). Other intervention names were less common.

The vast majority of trials in "David Geffen School of Medicine at UCLA" are 205 trials for "All" genders, 30 trials for "Male" genders and 6 trials for "Female" genders.

Currently, there are 46 active trials in "David Geffen School of Medicine at UCLA". 1 are not yet recruiting, 25 are recruiting, 19 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 145 completed trials in David Geffen School of Medicine at UCLA, 1 suspended trials, and 33 terminated clinical trials to date.

Out of the total trials that were conducted in David Geffen School of Medicine at UCLA, 32 "Phase 1" clinical trials were conducted, 90 "Phase 2" clinical trials and 89 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 16 trials, and there were also 17 trials that are defined as “Not Applicable".